Chasing Mylan, Hikma tries again with rejected generic Advai...

Hikma buys potential Epipen rival from troubled Insys

UK-based pharma Hikma has snapped up assets from embattled Insys Therapeutics, including potential generics of Mylan’s Epipen allergic reaction shot and a drug to reverse the effects of opi

Hikma rises on cancer generic deal with China’s Hansoh

UK-listed Hikma Pharma has licensed an array of injectable cancer drugs from China’s Hansoh, sparking a rise in its share price.

Ex-Teva exec to be new Hikma CEO

Hikma has a new chief executive after Said Darwazah, the son of the company’s late founder, Samih Darwazah, stepped aside.

Hikma in dispute with FDA over Advair generic

Hikma to give up date in Q1 next year.

GSK gets short term boost as second US Advair generic reject...

FDA rejects Hikma drug, regulator has "major" issue with Mylan's rival.